Previous 10 | Next 10 |
- $31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) toda...
2023-04-30 07:34:21 ET Summary Today, we circle back on Mirum Pharmaceuticals for the first time since late 2021. The stock has risen some 70% over that time thanks to the successful launch of Livmarli. The company also has numerous potential catalysts/milestones on the horizo...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first quarter 2023 financial results and recent corporate progress. Conference call details: Th...
2023-04-13 03:47:03 ET Mirum Pharmaceuticals ( NASDAQ: MIRM ) prices its offering of $275M aggregate principal amount of 4.00% convertible senior notes due 2029 in a private offering. The offering size was increased from the previously announced offering size of $200M agg...
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Ru...
2023-04-12 09:20:49 ET Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q1 Revenue of $31.5M. Approximately $232.1 million of cash, cash equivalents, restricted cash equivalents and short‐term investments as of March 31, 2023; These are all company...
2023-04-12 07:05:50 ET Mirum Pharmaceuticals ( NASDAQ: MIRM ) intends to offer $200M aggregate principal amount of convertible senior notes due 2029 in a private offering to qualified institutional buyers. The initial purchasers of the notes will have an option to purchase, fo...
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institut...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023. The company’s preliminary unaudited financial results for the first quarter of 2023 include: Approximately $31.5 million of tota...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Tim Walbert has been appointed to the company’s Board of Directors. In addition to Mr. Walbert’s appointment, the company shared that Niall O’Donnell, Ph.D., a Mirum director since November 2018, has announced hi...
News, Short Squeeze, Breakout and More Instantly...
Mirum Pharmaceuticals Inc. Company Name:
MIRM Stock Symbol:
NASDAQ Market:
Mirum Pharmaceuticals Inc. Website:
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the second quarter 2024 financial results and recent corporate progress. Conference call details: Wednesd...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive opinion from CHMP concluding LIVMARLI’s clinical benefit over existing therapy in PFIC. LIVMARLI also received positive COMP opinion recom...